PPD has appointed Darell Heiselman, D.O., to lead cardiovascular and critical care and David Klein, M.D., Ph.D., to oversee endocrinology, metabolism and diabetes. They bring extensive product development and commercialization experience to help clients capitalize on their drug development programs.
 
“PPD’s global team of scientific, medical and strategic experts provides our clients with expertise that helps reduce the time and cost associated with bringing medicines to market,” said Dr. Rob Dow, who oversees PPD’s therapeutic areas in his role as the company’s chief medical officer. “In their new roles, Darell and David will help develop cross-functional, integrated product development plans and assist with the design of clinical trials to provide therapeutic, protocol and site development expertise for our clients and their products.”
 
Dr. Heiselman, vice president of global product development, brings expertise in clinical research and internal medicine, with a focus on cardiovascular disease and critical care. During his 23 years of practice he developed a Critical Care Center of Excellence and performed more than 60 clinical trials in critical care, cardiology, nutritional support and stroke. Prior to joining PPD, he spent 11 years at Eli Lilly and Co. as a clinical research physician.
 
Dr. Klein, vice president of global product development, brings experience managing diabetes and endocrine clinical trials, as well as those in the therapeutic areas of pediatrics, rare diseases, obesity, lipid metabolism, nonalcoholic steatohepatitis and celiac disease. He has led teams through all phases of trials, first with Medpace for several years as medical director, then with Mankind Corp. as senior director of clinical development. Dr. Klein spent 22 years as tenured associate professor in pediatrics for the division of endocrinology and diabetes at the University of Minnesota, and Cincinnati Children’s Hospital Medical Center.